- Report
- May 2024
- 131 Pages
Global
From €6071EUR$6,499USD£5,136GBP
- Report
- June 2024
- 200 Pages
Global
From €7427EUR$7,950USD£6,283GBP
- Report
- January 2022
- 60 Pages
Global
From €3690EUR$3,950USD£3,122GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1168EUR$1,250USD£988GBP
- Clinical Trials
- December 2021
- 99 Pages
Global
From €2336EUR$2,500USD£1,976GBP
- Report
- August 2021
Global
From €3728EUR$3,990USD£3,153GBP
- Report
- February 2024
- 84 Pages
Global
From €3500EUR$4,013USD£3,065GBP
- Report
- May 2022
- 37 Pages
Global
From €1868EUR$2,000USD£1,581GBP
Raynaud's Disease is a disorder of the blood vessels, primarily affecting the fingers and toes. It is characterized by episodic vasospasms, which cause the affected areas to become cold and numb. Treatment for Raynaud's Disease typically involves lifestyle modifications, such as avoiding cold temperatures and stress, as well as medications.
Cardiovascular drugs are used to treat Raynaud's Disease, as they can help to reduce the frequency and severity of vasospasms. These drugs include calcium channel blockers, alpha blockers, and vasodilators. Calcium channel blockers work by blocking the influx of calcium into the cells, which helps to relax the blood vessels and reduce the frequency of vasospasms. Alpha blockers work by blocking the action of certain hormones, which can help to reduce the severity of vasospasms. Vasodilators work by widening the blood vessels, which can help to improve blood flow and reduce the frequency of vasospasms.
Some companies in the Raynaud's Disease Drug market include Pfizer, GlaxoSmithKline, Merck, and Novartis. Show Less Read more